|
Active substance |
Ipilimumab |
|
Holder |
BMS |
|
Status |
Closed |
|
Indication |
Treatment-Naïve Intermediate and Poor Risk Patients with Advanced or Metastatic Renal Cell Carcinoma in combination with Opdivo® (nivolumab) |
|
Public documents |
|
|
Last update |
10/01/2020 |
Yervoy
Last updated on 10/09/2024